Signal transduction and epigenetic mechanisms in the control of microglia activation during neuroinflammation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 3, 2016, Pages 339-351

  Kaminska, Bozena ^a   Mota, Mariana ^b   Pizzi, Marina ^b,c  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b UNIVERSITY OF BRESCIA   (Italy)

^c IRCCS   (Italy)

Author keywords

Epigenetics; HDAC inhibitors; Microglia; Neuroinflammation; Signaling pathways; Transcription regulation

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN;

ARTICLE; BRAIN ISCHEMIA; CHROMATIN STRUCTURE; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84957861141     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.10.026     Document Type: Article

References (188)

1. Amantea D., Micieli G., Tassorelli C., Cuartero M.I., Ballesteros I., Certo M., et al. Rational modulation of the innate immune system for neuroprotection in ischemic stroke. Front. Neurosci. 2015, 9:147.
2. Arthur J.S., Ley S.C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 2013, 13(9):679-692.
3. Bachstetter A.D., Van Eldik L.J. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis. 2010, 1(3):199-211.
4. Bachstetter A.D., Xing B., de Almeida L., Dimayuga E.R., Watterson D.M., Van Eldik L.J. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J. Neuroinflammation 2011, 8:79.
5. Baltan S., Bachleda A., Morrison R.S., Murphy S.P. Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia. Transl Stroke Res. 2011, 2(3):411-423.
6. Beamer C.A., Brooks D.M., Lurie D.I. Motheaten (me/me) mice deficient in SHP-are less susceptible to focal cerebral ischemia. J. Neurosci. Res. 2006, 83(7):1220-1230.
7. Beutner C., Linnartz-Gerlach B., Schmidt S.V., Beyer M., Mallmann M.R., Staratschek-Jox A., et al. Unique transcriptome signature of mouse microglia. Glia 2013, 61(9):1429-1442.
8. Bi Y., Liu G., Yang R. MicroRNAs: novel regulators during the immune response. J. Cell. Physiol. 2009, 218(3):467-472.
9. Bonaiuto C., McDonald P.P., Rossi F., Cassatella M.A. Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. J. Neuroimmunol. 1997, 77(1):51-56.
10. Brea D., Blanco M., Ramos-Cabrer P., Moldes O., Arias S., Pérez-Mato M., Leira R., Sobrino T., Castillo J. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J. Cereb. Blood Flow Metab. 2011, 31(6):1424-1431.
11. Breiling A., Lyko F. Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. Epigenetics Chromatin 2015, 8:24.
12. Brooks S.A., Blackshear P.J. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim. Biophys. Acta 2013, 1829(6-7):666-679.
13. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41(2-3):242-247.
14. Bruce A.J., Boling W., Kindy M.S., Peschon J., Kraemer P.J., Carpenter M.K., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 1996, 2(7):788-794.
15. Butovsky O., Jedrychowski M.P., Moore C.S., Cialic R., Lanser A.J., Gabriely G., et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 2014, 17(1):131-143.
16. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164(1-2):10-21.
17. Capiralla H., Vingtdeux V., Zhao H., Sankowski R., Al-Abed Y., Davies P., Marambaud P. Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J. Neurochem. 2012, 120(3):461-472.
18. Cardoso A.L., Guedes J.R. Pereira de Almeida L, Pedroso de Lima MC. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-and promoting cytokine and nitric oxide production. Immunology 2012, 135(1):73-88.
19. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biophys. Chem. 2005, 280(48):40364-40374.
20. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149(1):203-212.
21. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 2004, 5(5):392-401.
22. Cherry J.D., Olschowka J.A., O'Banion M.K. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation 2014, 11:98.
23. Chhor V., Le Charpentier T., Lebon S., Oré M.V., Celador I.L., Josserand J., et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun. 2013, 32:70-85.
24. Cho I.H., Hong J., Suh E.C., Kim J.H., Lee H., Lee J.E., Lee S., et al. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain 2008, 131(11):3019-3033.
25. Coppieters N., Dieriks B.V., Lill C., Faull R.L., Curtis M.A., Dragunow M. Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. Neurobiol. Aging 2014, 35(6):1334-1344.
26. Culbert A.A., Skaper S.D., Howlett D.R., Evans N.A., Facci L., Soden P.E., et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biophys. Chem. 2006, 281(33):23658-23666.
27. Dash P.K., Orsi S.A., Zhang M., Grill R.J., Pati S., Zhao J., et al. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 2010, 5(6).
28. Das A., Chai J.C., Kim S.H., Lee Y.S., Park K.S., Jung K.H., Chai Y.G. Transcriptome sequencing of microglial cells stimulated with TLR3 and TLR4 ligands. BMC Genomics 2015, 16:517.
29. Dempsey P.W., Doyle S.E., He J.Q., Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003, 14(3-4):193-209.
30. De Santa F., Totaro M.G., Prosperini E., Notarbartolo S., Testa G., Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007, 130(6):1083-1094.
31. De Souza C., Chatterji B.P. HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat. Anticancer Drug Discov. 2015, 10(2):145-162.
32. Dragone T., Cianciulli A., Calvello R., Porro C., Trotta T., Panaro M.A. Resveratrol counteracts lipopolysaccharide-mediated microglial inflammation by modulating a SOCS-dependent signaling pathway. Toxicol. in Vitro 2014, 28(6):1126-1135.
33. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-in microglial cells. Neuron 2006, 49(1):67-79.
34. Ellert-Miklaszewska A., Dabrowski M., Lipko M., Sliwa M., Maleszewska M., Kaminska B. Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia 2013, 61(7):1178-1190.
35. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70(6):1876-1884.
36. Fontana M.F., Baccarella A., Pancholi N., Pufall M.A., Herbert D.R., Kim C.C. JUNB is a key transcriptional modulator of macrophage activation. J. Immunol. 2015, 194(1):177-186.
37. Frakes A.E., Ferraiuolo L., Haidet-Phillips A.M., Schmelzer L., Braun L., Miranda C.J., et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 2014, 81(5):1009-1023.
38. Freilich R.W., Woodbury M.E., Ikezu T. Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia. PLoS One 2013, 8(11).
39. Fumagalli S., Perego C., Pischiutta F., Zanier E.R., De Simoni M.G. The ischemic environment drives microglia and macrophage function. Front. Neurol. 2015, 6:81.
40. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biophys. Chem. 2002, 277(28):25748-25755.
41. Ge Z., Da Y., Xue Z., Zhang K., Zhuang H., Peng M., et al. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp. Neurol. 2013, 241:56-66.
42. Gerstner T., Bell N., König S. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert. Opin. Pharmacother. 2008, 9(2):285-292.
43. Gesuete R., Kohama S.G., Stenzel-Poore M.P. Toll-like receptors and ischemic brain injury. J. Neuropathol. Exp. Neurol. 2014, 73(5):378-386.
44. Ghasemlou N., Lopez-Vales R., Lachance C., Thuraisingam T., Gaestel M., Radzioch D., David S. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury. J. Neurosci. 2010, 30(41):13750-13759.
45. Ginhoux F., Lim S., Hoeffel G., Low D., Huber T. Origin and differentiation of microglia. Front. Cell Neurosci. 2013, 7:45. (Apr 17). 10.3389/fncel.2013.00045.
46. Gisselbrecht S. The CIS/SOCS proteins: a family of cytokine-inducible regulators of signaling. Eur. Cytokine Netw. 1999, 10(4):463-470.
47. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140(6):918-934.
48. Goldmann T., Wieghofer P., Müller P.F., Wolf Y., Varol D., Yona S., et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat. Neurosci. 2013, 16(11):1618-1626.
49. Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15(8):509-524.
50. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10:32-42.
51. Häcker H., Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006, 2006(357). (re13).
52. Hajishengallis G., Lambris J.D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 2010, 31(4):154. Apr.
53. Hayden M.S., Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26(3):203-234.
54. Herdegen T., Waetzig V. AP-proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene 2001, 20(19):2424-2437.
55. Hickman S.E., Kingery N.D., Ohsumi T.K., Borowsky M.L., Wang L.C., Means T.K., et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 2013, 16(12):1896-1905.
56. Hidding U., Mielke K., Waetzig V., Brecht S., Hanisch U., Behrens A., et al. The c-Jun N-terminal kinases in cerebral microglia: immunological functions in the brain. Biochem. Pharmacol. 2002, 64(5-6):781-788.
57. Hinz M., Scheidereit C. The IκB kinase complex in NF-κB regulation and beyond. EMBO Rep. 2014, 15(1):46-61.
58. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(4):2041-2046.
59. Holtman I.R., Noback M., Bijlsma M., Duong K.N., van der Geest M.A., Ketelaars P.T., et al. Glia Open Access Database (GOAD): a comprehensive gene expression encyclopedia of glia cells in health and disease. Glia 2015, 63(9). 1495-06.
60. Horiuchi M., Wakayama K., Itoh A., Kawai K., Pleasure D., Ozato K., Itoh T. Interferon regulatory factor 8/interferon consensus sequence binding protein is a critical transcription factor for the physiological phenotype of microglia. J. Neuroinflammation 2012, 9:227.
61. Hu S., Chao C.C., Ehrlich L.C., Sheng W.S., Sutton R.L., Rockswold G.L., Peterson P.K. Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J. Leukoc. Biol. 1999, 65(6):815-821.
62. Huo Y., Rangarajan P., Ling E.A., Dheen S.T. Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia. BMC Neurosci. 2011, 12:49.
63. Huuskonen J., Suuronen T., Nuutinen T., Kyrylenko S., Salminen A. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br. J. Pharmacol. 2004, 141(5):874-880.
64. Hyakkoku K., Hamanaka J., Tsuruma K., Shimazawa M., Tanaka H., Uematsu S., Akira S., et al. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010, 171(1):258-267.
65. Iadecola C., Anrather J. The immunology of stroke: from mechanisms to translation. Nat. Med. 2011, 17(7):796-808.
66. Ikushima H., Negishi H., Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb. Symp. Quant. Biol. 2013, 78:105-116.
67. Ingrassia R., Lanzillotta A., Sarnico I., Benarese M., Blasi F., Borgese L., et al. 1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310. PLoS One 2012, 7(5).
68. Jin J.J., Kim H.D., Maxwell J.A., Li L., Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 2008, 5:23.
69. Ivashkiv L.B. Epigenetic regulation of macrophage polarization and function. Trends Immunol. 2013, 34(5):216-223.
70. Kaminska B., Pyrzynska B., Ciechomska I., Wisniewska M. Modulation of the composition of AP-complex and its impact on transcriptional activity. Acta Neurobiol. Exp. (Wars) 2000, 60(3). 395-02.
71. Kaminska B., Gozdz A., Zawadzka M., Ellert-Miklaszewska A., Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat. Rec. (Hoboken) 2009, 292(12):1902-1913.
72. Kannan V., Brouwer N., Hanisch U.K., Regen T., Eggen B.J., Boddeke H.W. Histone deacetylase inhibitors suppress immune activation in primary mouse microglia. J. Neurosci. Res. 2013, 91(9):1133-1142.
73. Kang Y.J., Chen J., Otsuka M., Mols J., Ren S., Wang Y., Han J. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J. Immunol. 2008, 180(7):5075-5082.
74. Kang K., Robinson G.W., Hennighausen L. Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics 2013, 14:4.
75. Karin M., Gallagher E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol. Rev. 2009, 228(1):225-240.
76. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
77. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34(5):637-650.
78. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7(10):854-868.
79. Keppler B.R., Archer T.K. Chromatin-modifying enzymes as therapeutic targets-Part 1. Expert Opin. Ther. Targets 2008, 12(10):1301-1312.
80. Keppler B.R., Archer T.K. Chromatin-modifying enzymes as therapeutic targets-Part 2. Expert Opin. Ther. Targets 2008, 12(11):1457-1467.
81. Khorooshi R., Owens T. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J. Immunol. 2010, 185(2):1258-1264.
82. Kimura A., Naka T., Muta T., Takeuchi O., Akira S., Kawase I., Kishimoto T. Suppressor of cytokine signaling-selectively inhibits LPS-induced IL-production by regulating JAK-STAT. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(47):17089-17094.
83. Kiernan R., Brès V., Ng R.W., Coudart M.P., El Messaoudi S., Sardet C., et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003, 278(4). 2758-66.
84. Kigerl K.A., de Rivero Vaccari J.P., Dietrich W.D., Popovich P.G., Keane R.W. Pattern recognition receptors and central nervous system repair. Exp Neuro. 2014, 258:5-16.
85. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35(4):870-880.
86. Kilic U., Kilic E., Matter C.M., Bassetti C.L., Hermann D.M. TLR-deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol. Dis. 2008, 31(1):33-40.
87. Kim E.J., Kim Y.H., Rook A.H., Lerner A., Duvic M., Reddy S., et al. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk. Lymphoma 2015, 1-8.
88. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321(3):892-901.
89. Kim C., Ho D.H., Suk J.E., You S., Michael S., Kang J., Joong Lee S., Masliah E., Hwang D., Lee H.J., Lee S.J. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, 4:1562.
90. Koizumi S., Ohsawa K., Inoue K., Kohsaka S. Purinergic receptors in microglia: functional modal shifts of microglia mediated by P2 and P1 receptors. Glia 2013, 61(1):47-54.
91. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1999, 1(2):94-97.
92. Lambertsen K.L., Clausen B.H., Babcock A.A., Gregersen R., Fenger C., Nielsen H.H., et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J. Neurosci. 2009, 29(5):1319-1330.
93. Lampron A., Elali A., Rivest S. Innate immunity in the CNS: redefining the relationship between the CNS and Its environment. Neuron 2013, 78(2):214-232.
94. Lanzillotta A., Sarnico I., Ingrassia R., Boroni F., Branca C., Benarese M., et al. The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis. 2010, 1.
95. Lanzillotta A., Pignataro G., Branca C., Cuomo O., Sarnico I., Benarese M., et al. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiol. Dis. 2013, 49:177-189.
96. Lee J.T., Chou C.H., Cho N.Y., Sung Y.F., Yang F.C., Chen C.Y., et al. Post-insult valproate treatment potentially improved functional recovery in patients with acute middle cerebral artery infarction. Am. J. Transl. Res. 2014, 6(6):820-830.
97. Lehnardt S., Lehmann S., Kaul D., Tschimmel K., Hoffmann O., Cho S., Krueger C., Nitsch R., Meisel A., Weber J.R. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J. Neuroimmunol. 2007, 190(1-2):28-33.
98. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58(3):253-263.
99. Li H.S., Watowich S.S. Innate immune regulation by STAT-mediated transcriptional mechanisms. Immunol. Rev. 2014, 261(1):84-101.
100. Li L., Sun Q., Li Y., Yang Y., Chang T., Man M., et al. Overexpression of SIRT1 induced by resveratrol and inhibitor of miR-204 suppresses activation and proliferation of microglia. J. Mol. Neurosci. 2015.
101. Liu F., Xia Y., Parker A.S., Verma I.M. IKK biology. Immunol. Rev. 2012, 246(1):239-253.
102. Liu G., Abraham E. MicroRNAs in immune response and macrophage polarization. Arterioscler. Thromb. Vasc. Biol. 2013, 33(2):170-177.
103. Lim J.E., Kou J., Song M., Pattanayak A., Jin J., Lalonde R., Fukuchi K. MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am. J. Pathol. 2011, 179(3):1095-1103.
104. Liu L., Doran S., Xu Y., Manwani B., Ritzel R., Benashski S., et al. Inhibition of mitogen-activated protein kinase phosphatase-(MKP-1) increases experimental stroke injury. Exp. Neurol. 2014, 261:404-411.
105. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal. 2002, 14(6):477-492.
106. Magnus T., Wiendl H., Kleinschnitz C. Immune mechanisms of stroke. Curr. Opin. Neurol. 2012, 25(3):334-340.
107. Majdzadeh N., Morrison B.E., D'Mello S.R. Class IIA HDACs in the regulation of neurodegeneration. Front. Biosci. 2008, 13:1072-1082.
108. Marsh B.J., Williams-Karnesky R.L., Stenzel-Poore M.P. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009, 158(3):1007-1020.
109. Masuda T., Tsuda M., Yoshinaga R., Tozaki-Saitoh H., Ozato K., Tamura T., Inoue K. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Re 2012, 1(4):334-340.
110. Masuda T., Nishimoto N., Tomiyama D., Matsuda T., Tozaki-Saitoh H., Tamura T., et al. IRF8 is a transcriptional determinant for microglial motility. Purinergic Signal 2014, 10(3):515-521.
111. Mattson M.P., Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 2001, 107(3):247-254.
112. Mead E.L., Mosley A., Eaton S., Dobson L., Heales S.J., Pocock J.M. Microglial neurotransmitter receptors trigger superoxide production in microglia; consequences for microglial-neuronal interactions. J. Neurochem. 2012, 121(2). 287-30.
113. Michaud J.P., Richard K.L., Rivest S. Hematopoietic MyD88-adaptor protein acts as a natural defense mechanism for cognitive deficits in Alzheimer's disease. Stem Cell Rev. 2012, 8(3):898-904.
114. Minten C., Terry R., Deffrasnes C., King N.J., Campbell I.L. IFN regulatory factor 8 is a key constitutive determinant of the morphological and molecular properties of microglia in the CNS. PLoS One 2012, 7(11).
115. Miyamoto A., Wake H., Moorhouse A.J., Nabekura J. Microglia and synapse interactions: fine tuning neural circuits and candidate molecules. Front. Cell. Neurosci. 2013, 7:70.
116. Neumann H., Kotter M.R., Franklin R.J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132(Pt 2):288-295.
117. Ni J., Wang X., Chen S., Liu H., Wang Y., Xu X., et al. MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. Brain Behav. Immun. 2015, 49:75-85.
118. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308(5726):1314-1318.
119. Nomaru H., Sakumi K., Katogi A., Ohnishi Y.N., Kajitani K., Tsuchimoto D., et al. Fosb gene products contribute to excitotoxic microglial activation by regulating the expression of complement C5a receptors in microglia. Glia 2014, 62(8):1284-1298.
120. North B.J., Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 2004, 5(5):224.
121. Olah M., Amor S., Brouwer N., Vinet J., Eggen B., Biber K., Boddeke H.W. Identification of a microglia phenotype supportive of remyelination. Glia 2012, 60(2):306-321.
122. Owens T., Khorooshi R., Wlodarczyk A., Asgari N. Interferons in the central nervous system: a few instruments play many tunes. Glia 2014, 62(3):339-355.
123. O'Shea J.J., Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012, 36(4):542-550.
124. Pizzi M., Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur. J. Pharmacol. 2006, 545(1):22-28.
125. Peserico A., Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol. 2011, 2011:371832.
126. Ponomarev E.D., Veremeyko T., Barteneva N., Krichevsky A.M., Weiner H.L. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat. Med. 2011, 17(1):64-70.
127. Przanowski P., Dabrowski M., Ellert-Miklaszewska A., Kloss M., Mieczkowski J., Kaza B., et al. The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia. J. Mol. Med.(Berl) 2014, 92(3):239-254.
128. Qin H., Yeh W.I., De Sarno P., Holdbrooks A.T., Liu Y., Muldowney M.T., et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-(STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(13):5004-5009.
129. Qing H., He G., Ly P.T., Fox C.J., Staufenbiel M., Cai F., et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med. 2008, 205(12):2781-2789.
130. Qiu L.Q., Stumpo D.J., Blackshear P.J. Myeloid-specific tristetraprolin deficiency in mice results in extreme lipopolysaccharide sensitivity in an otherwise minimal phenotype. J. Immunol. 2012, 188(10):5150-5159.
131. Ren M., Leng Y., Jeong M., Leeds P.R., Chuang D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 2004, 89(6):1358-1367.
132. Richard K.L., Filali M., Préfontaine P., Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28(22):5784-5793.
133. Ridder D.A., Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience 2009, 158(3):995-1006.
134. Romero-Sandoval E.A., Horvath R., Landry R.P., DeLeo J.A. Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain. 2009, 5:25.
135. Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-during neurodegeneration. EMBO J 2003, 22(24):6537-6549.
136. Rubartelli A., Lotze M.T. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007, 28(10):429-436.
137. Saha R.N., Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006, 13(4):539-550.
138. Salojin K., Oravecz T. Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes. J. Leukoc. Biol. 2007, 81(4):860-869.
139. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biophys. Chem. 2007, 282(28):20059-20063.
140. Shein N.A., Grigoriadis N., Alexandrovich A.G., Simeonidou C., Lourbopoulos A., Polyzoidou E., et al. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 2009, 23(12):4266-4275.
141. Singh V., Bhatia H.S., Kumar A., de Oliveira A.C., Fiebich B.L. Histone deacetylase inhibitors valproic acid and sodium butyrate enhance prostaglandins release in lipopolysaccharide-activated primary microglia. Neuroscience 2014, 265:147-157.
142. Singh P., Dejager L., Amand M., Theatre E., Vandereyken M., Zurashvili T., et al. DUSP3 Genetic Deletion Confers M2-like Macrophage-Dependent Tolerance to Septic Shock. J. Immunol. 2015, 194(10):4951-4962.
143. Solga A.C., Pong W.W., Walker J., Wylie T., Magrini V., Apicelli A.J., et al. RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia 2015, 63(4):531-548.
144. Solt L.A., Madge L.A., Orange J.S., May M.J. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. J. Biophys. Chem. 2007, 282(12):8724-8733.
145. Song M., Jin J., Lim J.E., Kou J., Pattanayak A., Rehman J.A., et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation 2011, 8:92.
146. Sullivan P.G., Bruce-Keller A.J., Rabchevsky A.G., Christakos S., Clair D.K., Mattson M.P., Scheff S.W. Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J. Neurosci. 1999, 19(15):6248-6256.
147. Suh H.S., Choi S., Khattar P., Choi N., Lee S.C. Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J. NeuroImmune Pharmacol. 2010, 5(4):521-532.
148. Sung Y.M., Lee T., Yoon H., DiBattista A.M., Song J.M., Sohn Y., et al. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp. Neurol. 2013, 239:192-201.
149. Suuronen T., Huuskonen J., Nuutinen T., Salminen A. Characterization of the pro-inflammatory signaling induced by protein acetylation in microglia. Neurochem. Int. 2006, 49(6):610-618.
150. Suuronen T., Huuskonen J., Pihlaja R., Kyrylenko S., Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J. Neurochem. 2003, 87(2):407-416.
151. Takaoka A., Yanai H., Kondo S., Duncan G., Negishi H., Mizutani T., et al. Integral role of IRF-in the gene induction programme activated by Toll-like receptors. Nature 2005, 434(7030):243-249.
152. Tan J., Town T., Mori T., Wu Y., Saxe M., Crawford F., Mullan M. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J. Neurosci. 2000, 20(20):7587-7594.
153. Tanaka T., Murakami K., Bando Y., Yoshida S. Interferon regulatory factor 7 participates in the M1-like microglial polarization switch. Glia 2015, 63(4):595-610.
154. Taylor D.L., Diemel L.T., Cuzner M.L., Pocock J.M. Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J. Neurochem. 2002, 82(5):1179-1189.
155. Taylor D.L., Jones F., Kubota E.S., Pocock J.M. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J. Neurosci. 2005, 25(11):2952-2956.
156. Tessarz P., Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 2014, 15(11):703-711.
157. Thomas E.A., Coppola G., Desplats P.A., Tang B., Soragni E., Burnett R., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(40):15564-15569.
158. Thuraisingam T., Xu Y.Z., Moisan J., Lachance C., Garnon J., Di Marco S., Gaestel M., Radzioch D. Distinct role of MAPKAPK-in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands. Mol. Immunol. 2007, 44(14):3482-3491.
159. Tsuda M., Toyomitsu E., Kometani M., Tozaki-Saitoh H., Inoue K. Mechanisms underlying fibronectin-induced up-regulation of P2X4R expression in microglia: distinct roles of PI3K-Akt and MEK-ERK signalling pathways. J. Cell. Mol. Med. 2009, 13(9B):3251-3259.
160. Urra X., Villamor N., Amaro S., Gómez-Choco M., Obach V., Oleaga L., Planas A.M., Chamorro A. Monocyte subtypes predict clinical course and prognosis in human stroke. J. Cereb. Blood Flow Metab. 2009, 29(5):994-1002.
161. Waetzig V., Czeloth K., Hidding U., Mielke K., Kanzow M., Brecht S., et al. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 2005, 50(3):235-246.
162. Wang G., Jiang X., Pu H., Zhang W., An C., Hu X., et al. Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway: scriptaid protects against TBI via AKT. Neurotherapeutics 2013, 10(1):124-142.
163. Wang L.W., Chang Y.C., Chen S.J., Tseng C.H., Tu Y.F., Liao N.S., Huang C.C., Ho C.J. TNFR1-JNK signaling is the shared pathway of neuroinflammation and neurovascular damage after LPS-sensitized hypoxic-ischemic injury in the immature brain. J Neuroinflamm 2014, 24(11):215.
164. Wang G., Shi Y., Jiang X., Leak R.K., Hu X., Wu Y., et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(9):2853-2858.
165. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138(5):1019-1031.
166. Woodling N.S., Wang Q., Priyam P.G., Larkin P., Shi J., Johansson J.U., et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci. 2014, 34(17):5882-5894.
167. Waskiewicz A.J., Johnson J.C., Penn B., Mahalingam M., Kimball S.R., Cooper J.A. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol. Cell. Biol. 1999, 19(3):1871-1880.
168. Weitz T.M., Gate D., Rezai-Zadeh K., Town T. MyD88 is dispensable for cerebral amyloidosis and neuroinflammation in APP/PS1 transgenic mice. Am. J. Pathol. 2014, 184(11):2855-2861.
169. Wieghofer P., Knobeloch K.P., Prinz M. Genetic targeting of microglia. Glia 2015, 63(1):1-22.
170. Xing B., Bachstetter A.D., Van Eldik L.J. Deficiency in p38β MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models. PLoS One 2013, 8(2).
171. Xuan A., Long D., Li J., Ji W., Hong L., Zhang M., et al. Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci. 2012, 90(11-12):463-468.
172. Yang Q.W., Li J.C., Lu F.L., Wen A.Q., Xiang J., Zhang L.L., Huang Z.Y., Wang J.Z. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J. Cereb. Blood Flow Metab. 2008, 28(9):1588-1596.
173. Yang Z., Zhong L., Zhong S., Xian R., Yuan B. miR-203 protects microglia mediated brain injury by regulating inflammatory responses via feedback to MyD88 in ischemia. Mol. Immunol. 2015, 65(2):293-301.
174. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23(12):2369-2380.
175. Yildirim F., Gertz K., Kronenberg G., Harms C., Fink K.B., Meisel A., et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol. 2008, 210(2):531-542.
176. Yoshimura A., Ohkubo T., Kiguchi T., Jenkins N.A., Gilbert D.J., Copeland N.G., et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995, 14(12):2816-2826.
177. Zawadzka M., Dabrowski M., Gozdz A., Szadujkis B., Sliwa M., Lipko M., Kaminska B. Early steps of microglial activation are directly affected by neuroprotectant FK506 in both in vitro inflammation and in rat model of stroke. J. Mol. Med.(Berl) 2012, 90(12):1459-1471.
178. Zhao Q., Wang X., Nelin L.D., Yao Y., Matta R., Manson M.E., et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 2006, 203(1):131-140.
179. Zhao J., Brooks D.M., Lurie D.I. Lipopolysaccharide-activated SHP-1-deficient motheaten microglia release increased nitric oxide, TNF-alpha, and IL-1beta. Glia 2006, 53(3):304-312.
180. Zhang L., Dong L.Y., Li Y.J., Hong Z., Wei W.S. miR-21 represses FasL in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia. Glia 2012, 60(12):1888-1895.
181. Zhang L., Dong L.Y., Li Y.J., Hong Z., Wei W.S. The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor. J Neuroinflammation 2012, 9:211.
182. Zhang L., Li Y.J., Wu X.Y., Hong Z., Wei W.S. MicroRNA-181c negatively regulates the inflammatory response in oxygen-glucose-deprived microglia by targeting Toll-like receptor 4. J. Neurochem. 2015, 132(6):713-723.
183. Zhao H., Wang J., Gao L., Wang R., Liu X., Gao Z., et al. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke 2013, 44(6):1706-1713.
184. Zhao G.N., Jiang D.S., Li H. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim. Biophys. Acta 2015, 1852(2):365-378.
185. Zhou Y., Ling E.A., Dheen S.T. Dexamethasone suppresses monocyte chemoattractant protein-production via mitogen activated protein kinase phosphatase-dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J. Neurochem. 2007, 102(3):667-678.
186. Micelli C., Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov. Today 2015, 20(6):718-735. (Jun).
187. Inta I., Paxian S., Maegele I., Zhang W., Pizzi M., Spano P., Sarnico I., Muhammad S., Herrmann O., Inta D., Baumann B., Liou H.C., Schmid R.M., Schwaninger M. Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J. Neurosci. 2006, 26(50):12896-12903.
188. Sarnico I., Lanzillotta A., Boroni F., Benarese M., Alghisi M., Schwaninger M., Inta I., Battistin L., Spano P., Pizzi M. NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J. Neurochem. 2009, 108(2):475-485.